Lupin gained 2.83% to Rs 717 at 13:35 IST on BSE on reporting 38.45% rise in net profit to Rs 108.52 crore in Q1 June 2008 over Q1 June 2007.
The company announced the results during trading hours today, 22 July 2008.
The stock hit a high of Rs 725 and a low of Rs 690.30 so far during the day. The stock had a 52-week high of Rs 741.90 on 13 June 2008 and a 52-week low of Rs 429.90 on 22 January 2008.
The company has an equity capital of Rs 82.09 crore. Face value per share is Rs 10.
The current price of Rs 717 discounts its Q4 March 2008 annualised EPS of Rs 37.35, by a PE multiple of 19.20.
The company’s total income rose 18.39% to Rs 712.42 crore in Q1 June 2008 over Q1 June 2007.
On 24 June 2008, Lupin entered into an agreement with US based Ascend Therapeutics Inc for promoting suprax 400 miligram tablets in the US market.
On 16 June 2008, Lupin received a tentative approval from US Food & Drug Administration (USFDA) for its escitalopram oxalate tablets in 10 & 20-milligram strengths.
Lupin is engaged in manufacturing active pharmaceutical ingredients and formulations.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment